1. Home
  2. DAWN vs MCB Comparison

DAWN vs MCB Comparison

Compare DAWN & MCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DAWN
  • MCB
  • Stock Information
  • Founded
  • DAWN 2018
  • MCB 1999
  • Country
  • DAWN United States
  • MCB United States
  • Employees
  • DAWN N/A
  • MCB 293
  • Industry
  • DAWN Biotechnology: Pharmaceutical Preparations
  • MCB Major Banks
  • Sector
  • DAWN Health Care
  • MCB Finance
  • Exchange
  • DAWN Nasdaq
  • MCB Nasdaq
  • Market Cap
  • DAWN 624.8M
  • MCB 685.1M
  • IPO Year
  • DAWN 2021
  • MCB 2017
  • Fundamental
  • Price
  • DAWN $9.14
  • MCB $66.21
  • Analyst Decision
  • DAWN Strong Buy
  • MCB Buy
  • Analyst Count
  • DAWN 8
  • MCB 2
  • Target Price
  • DAWN $27.63
  • MCB $82.00
  • AVG Volume (30 Days)
  • DAWN 1.9M
  • MCB 144.1K
  • Earning Date
  • DAWN 11-04-2025
  • MCB 10-23-2025
  • Dividend Yield
  • DAWN N/A
  • MCB 0.91%
  • EPS Growth
  • DAWN N/A
  • MCB 8.50
  • EPS
  • DAWN N/A
  • MCB 5.80
  • Revenue
  • DAWN $133,672,000.00
  • MCB $261,456,000.00
  • Revenue This Year
  • DAWN $12.88
  • MCB $15.57
  • Revenue Next Year
  • DAWN $48.27
  • MCB $13.99
  • P/E Ratio
  • DAWN N/A
  • MCB $11.42
  • Revenue Growth
  • DAWN 31.11
  • MCB 1.27
  • 52 Week Low
  • DAWN $5.64
  • MCB $47.08
  • 52 Week High
  • DAWN $16.76
  • MCB $81.33
  • Technical
  • Relative Strength Index (RSI)
  • DAWN 71.77
  • MCB 34.20
  • Support Level
  • DAWN $7.11
  • MCB $71.37
  • Resistance Level
  • DAWN $7.62
  • MCB $67.05
  • Average True Range (ATR)
  • DAWN 0.47
  • MCB 2.54
  • MACD
  • DAWN 0.10
  • MCB -0.69
  • Stochastic Oscillator
  • DAWN 72.26
  • MCB 9.24

About DAWN Day One Biopharmaceuticals Inc.

Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.

About MCB Metropolitan Bank Holding Corp.

Metropolitan Bank Holding Corp is a bank holding company. It provides a broad range of business, commercial, and retail banking products and services to small businesses, middle-market enterprises, public entities, and individuals in the New York metropolitan area. The services provided by the company include deposits, trade finance, cash management solutions, savings, electronic banking, cards, and others. The company also provides various lending products such as acquisition loans, construction loans, and lines of credit, for retail, office, hospitality, multifamily, mixed-use, warehouse and distribution, and specialty-use properties. The bank derives its revenue in the form of interest income on loans.

Share on Social Networks: